REVLIMID LAWSUIT STATUS: The potential for litigation involving Revlimid is being reviewed by Stevens-Johnson Syndrome lawyers on behalf of individuals who have been diagnosed with SJS or TEN after receiving the drug.
MANUFACTURER: Celgen Corp.
OVERVIEW: Revlimid (lenalidomide) is an immunomodulatory agent approved for treatment of a bone marrow disorder known as myelodysplastic syndrome and for multiple myeloma, which is a type of blood cancer.
The FDA originally approved Revlimid in December 2005, and it has been used by about 60,000 people.
REVLIMID STEVENS-JOHNSON SYNDROME SIDE EFFECTS: In September 2008, the FDA confirmed that they are investigating a potential association between Revlimid and Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Post-marketing reports have been received of at least 14 cases of the severe skin reactions associated with Revlimid side effects.
Stevens-Johnson syndrome and toxic epidermal necrolysis result in a severe rash and blistering of the skin, mouth, eyes and genitals, where the skin literally burns from the inside out. The condition often requires treatment in an ICU or Burn Unit and could be fatal in severe cases.
A number of different medications have been the subject of litigation filed by Stevens-Johnson syndrome and toxic epidermal necrolysis lawyers, alleging that the drugs did not contain adequate warnings about the possible skin reaction.
Potential lawsuits are being evaluated by Revlimid lawyers as a result of Celgen Corp.’s failure to properly warn about these debilitating and life-threatening problems. After the FDA announced that they were reviewing the association between Revlimid and SJS/TEN, Celgen Corp. indicated that they would likely update the warning label to include information about reports of Stephens-Johnson syndrome and Toxic Epidermal Necrolysis.